Kingworld Medicines Group Limited (HKG:1110)
Hong Kong · Delayed Price · Currency is HKD 0.4000
+0.0050 (1.27%)
Sep 11, 2026, 4:08 PM HKT
Kingworld Medicines Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 787.87 | 917.34 | 1,061 | 1,079 | 957.7 | 847.39 | |
Revenue Growth | -16.17% | -13.55% | -1.63% | 12.63% | 13.02% | 13.69% |
Cost of Revenue | 547.83 | 669.44 | 790.64 | 797.99 | 680.07 | 583.79 |
Gross Profit | 240.04 | 247.91 | 270.45 | 280.67 | 277.63 | 263.6 |
Selling, General & Admin | 164.49 | 176.89 | 189.5 | 203.59 | 205.03 | 196.16 |
Research & Development | 21.8 | 21.8 | 17.59 | 18.84 | - | - |
Amortization of Goodwill & Intangibles | - | - | - | - | 13.57 | 13.57 |
Other Operating Expenses | -4.7 | -7.59 | -30 | -20.88 | -22.35 | -17.42 |
Operating Expenses | 181.7 | 191.2 | 177.29 | 201.99 | 197.29 | 192.36 |
Operating Income | 58.34 | 56.7 | 93.16 | 78.68 | 80.34 | 71.24 |
Interest Expense | -14.55 | -14.05 | -13.28 | -11.52 | -12.29 | -11.78 |
Interest & Investment Income | 12.21 | 8.9 | 8.36 | 11.52 | 1.75 | 2.8 |
Earnings From Equity Investments | 6.56 | 8.32 | 19.1 | 8.6 | 7.64 | 8.99 |
Currency Exchange Gain (Loss) | -1.57 | -1.03 | -10.19 | -4.97 | -5.81 | -3.09 |
Other Non Operating Income (Expenses) | - | - | -2.91 | - | - | - |
EBT Excluding Unusual Items | 61 | 58.84 | 94.23 | 82.31 | 71.63 | 68.16 |
Gain (Loss) on Sale of Investments | -8.14 | -8.32 | -4.25 | 12.94 | 2.89 | 0.47 |
Asset Writedown | 6.3 | 6.84 | 5.16 | -1.36 | -7.3 | 0.8 |
Other Unusual Items | 0.07 | 0.07 | 0.37 | - | 0.36 | - |
Pretax Income | 59.23 | 57.43 | 95.52 | 93.89 | 67.58 | 69.43 |
Income Tax Expense | 24.21 | 18.54 | 21.05 | 32.29 | 24.04 | 18.22 |
Earnings From Continuing Operations | 35.02 | 38.89 | 74.47 | 61.59 | 43.54 | 51.21 |
Minority Interest in Earnings | -23.55 | -27.61 | -32.91 | -23.5 | -20.8 | -20.89 |
Net Income | 11.47 | 11.28 | 41.56 | 38.1 | 22.74 | 30.32 |
Net Income to Common | 11.47 | 11.28 | 41.56 | 38.1 | 22.74 | 30.32 |
Net Income Growth | 111.27% | -72.85% | 9.09% | 67.52% | -24.99% | 158.78% |
Shares Outstanding (Basic) | 591 | 586 | 576 | 592 | 607 | 607 |
Shares Outstanding (Diluted) | 591 | 586 | 576 | 592 | 607 | 607 |
Shares Change | 4.02% | 1.78% | -2.66% | -2.49% | 0.04% | -1.29% |
EPS (Basic) | 0.02 | 0.02 | 0.07 | 0.06 | 0.04 | 0.05 |
EPS (Diluted) | 0.02 | 0.02 | 0.07 | 0.06 | 0.04 | 0.05 |
EPS Growth | 103.11% | -73.33% | 12.06% | 71.79% | -25.02% | 162.17% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 54.92 | 94.73 | -63.25 | 93.04 | 22.88 |
Free Cash Flow Per Share | - | 0.09 | 0.16 | -0.11 | 0.15 | 0.04 |
Dividend Per Share | - | - | 0.030 | 0.031 | 0.022 | 0.019 |
Dividend Growth | - | - | -2.87% | 40.74% | 11.79% | 254.55% |
Gross Margin | 30.47% | 27.02% | 25.49% | 26.02% | 28.99% | 31.11% |
Operating Margin | 7.41% | 6.18% | 8.78% | 7.29% | 8.39% | 8.41% |
Profit Margin | 1.46% | 1.23% | 3.92% | 3.53% | 2.38% | 3.58% |
Free Cash Flow Margin | - | 5.99% | 8.93% | -5.86% | 9.71% | 2.70% |
EBITDA | 73.33 | 72.03 | 104.64 | 88.52 | 107.39 | 96.46 |
EBITDA Margin | 9.31% | 7.85% | 9.86% | 8.21% | 11.21% | 11.38% |
D&A For EBITDA | 14.99 | 15.33 | 11.49 | 9.84 | 27.05 | 25.22 |
EBIT | 58.34 | 56.7 | 93.16 | 78.68 | 80.34 | 71.24 |
EBIT Margin | 7.41% | 6.18% | 8.78% | 7.29% | 8.39% | 8.41% |
Effective Tax Rate | 40.87% | 32.28% | 22.04% | 34.39% | 35.57% | 26.25% |